The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®
From (1)Mayo Clinic and M Health Fairview, Rochester, Minnesota; (2)Ballad Health Cancer Care-Bristol, Bristol, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Kirollos Hanna, PharmD, BCPS, BCOP, 200 First St. SW, Rochester, MN 55905. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2021;12(2):13–20 |
© 2021 Harborside™
Almost all patients with breast cancer will eventually receive chemotherapy drugs, the majority of which are administered as IV infusions. Real-world evidence indicates that while current treatment paradigms vary considerably from guideline recommendations, there is an increasing trend towards a preference for oral oncolytics among patients with breast cancer. Recent data have shown that oral anticancer therapeutics represent 25% of the oncology drug market share and that there is a high demand for these agents. Therefore, oral formulations of chemotherapy agents such as paclitaxel are currently under development. Although oral oncolytics are associated with several advantages over conventional intravenous drugs, maintaining adherence to therapy is a major barrier in achieving improved outcomes with these agents. Advanced practitioners can facilitate improved adherence to oral oncolytics by integrating evidence into practice to support better education and communication strategies to address patient concerns, overcome key hurdles, and ultimately, empower patients.
For access to the full length article, please sign in